The health reporter Kim Schewitz often feels tired, and hoped tracking her blood sugar levels using a continuous glucose ...

As of Friday, January 30, Senseonics Holdings, Inc.’s SENS share price has surged by 7.18%, which has investors questioning if this is right time to sell.

As of the January 28 closing, DexCom Inc. (NASDAQ:DXCM) had highly bullish sentiment according to consensus. Out of 22 analysts who covered the stock, 18 assigned Buy ratings and 3 gave Hold calls.

Senseonics Holdings, Inc. SENS recently scored a meaningful regulatory win in Europe, receiving CE Mark approval for its ...

The company is hiring sales reps and transitioning staff from its former partner to support launches in Germany, Italy, Spain ...

Letitia explains how a small medical device, designed to help manage the illness, is now blamed for sending hundreds of ...

Senseonics (NYSE:SENS) announced today that its Eversense 365 continuous glucose monitor (CGM) system received CE mark ...

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

WAN CHAI, WAN CHAI, HONG KONG, January 23, 2026 /EINPresswire.com/ -- Even with the advancement of Automated Insulin ...

Glucotrack (Nasdaq:GCTK) announced today that it received new U.S. patents for its continuous blood glucose monitoring (CBGM) ...

DexCom Inc. (NASDAQ:DXCM) is a medical device company that focuses on the design, development, and commercialization of CGM (continuous glucose monitoring) systems in the US and internationally.

Researchers conducted an observational cross-sectional study to assess how interoceptive awareness affects recognition of hypoglycemia in type 1 diabetes.